Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement

ANNX +4.17%

Annexon, Inc. (NASDAQ:ANNX) is one of the 12 hot penny stocks to invest in right now.

On November 19, 2025, The Fly reported that Wells Fargo increased its price target on Annexon, Inc. (NASDAQ:ANNX) from $14 to $27, while reiterating an “Overweight” rating. The investment firm’s price revision reflects its increased probability of success in the second half of 2026 for vonaprument’s Phase 3 trial in GA to 55% from 10%. The firm believes the program offers a significant, asymmetric risk-reward skew with massive upside in the next 12 months.

Meanwhile, Annexon, Inc. (NASDAQ:ANNX) reported Q3 2025 results on November 10. Posting $54.9 million, or $0.37 per share, in net loss for the quarter, the company’s R&D expenses increased to $49.7 million due to advancement of vonaprument’s Phase 3 ARCHER II trial and global filings for tanruprubart in GBS. On the other hand, G&A expenses decreased, thanks to the company’s operational efficiencies.

Annexon, Inc. (NASDAQ:ANNX) closed the quarter with $188.7 million in cash, providing a runway into early 2027. The company’s neuroinflammation platform also noted progress, with EU Marketing Authorization Application (MAA) submission for tanruprubart in January 2026 and topline ARCHER II data for vonaprument expected in the second half of 2026.

Annexon, Inc. (NASDAQ:ANNX) is focused on developing innovative complement inhibitors targeting neuroinflammation across autoimmunity, neurodegeneration, and ophthalmology.

While we acknowledge the potential of ANNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.

Disclosure: None.